4//SEC Filing
BIOMET INC 4
Accession 0000769993-07-000952
CIK 0000351346operating
Filed
Sep 18, 8:00 PM ET
Accepted
Sep 19, 6:43 PM ET
Size
13.2 KB
Accession
0000769993-07-000952
Insider Transaction Report
Form 4
BIOMET INCBMET
Fernandes Sean
Director
Transactions
- Exercise of In-MoneySwap
Security Based Swap (put equivalent)
2007-08-17−1,400→ 0 total(indirect: See footnotes)Exp: 2017-04-07→ Common Shares (1,400 underlying) - Exercise of In-MoneySwap
Security Based Swap (put equivalent)
2007-08-17−20,200→ 0 total(indirect: See footnotes)Exp: 2017-04-10→ Common Shares (20,200 underlying)
Holdings
- 124,282(indirect: See footnotes)
Common Shares
- 3,100(indirect: See footnotes)
Call Option (right to purchase)
Exercise: $45.00Exp: 2009-01-17→ Common Shares (3,100 underlying)
Footnotes (5)
- [F1]The Reporting Person is a vice president of Goldman, Sachs & Co. ("Goldman Sachs"). Goldman Sachs is a wholly-owned subsidiary of The Goldman Sachs Group, Inc. ("GS Group"). Goldman Sachs is affiliated with private equity funds that hold equity interests in LVB Acquisition Holding, LLC, the indirect beneficial owner of 208,324,725 common shares, no par value (the "Common Shares") of Biomet, Inc. (the "Company"), including 5,723,595 Common Shares beneficially owned by Dr. Dane A. Miller and Mary Louise Miller that are subject to a voting agreement with LVB Acquisition, Inc., a subsidiary of LVB Acquisition Holding, LLC. In addition, Goldman Sachs and other wholly-owned subsidiaries of GS Group (collectively, "Goldman") may be deemed to directly beneficially own 124,282 Common Shares.
- [F2]The Reporting Person disclaims beneficial ownership of all of the securities reported on Table I and Table II of this Form 4, including the Common Shares that are or may be beneficially owned by LVB Acquisition Holding, LLC, Goldman Sachs, other wholly-owned subsidiaries of GS Group and any of their affiliated funds. The securities reported herein as indirectly beneficially owned may be deemed to be beneficially owned by Goldman.
- [F3]On August 17, 2007, upon the accelerated settlement of a security-based swap agreement in the form of a contract for difference entered into on April 10, 2007, Goldman Sachs International ("GSI"), a wholly-owned subsidiary of GS Group, paid to its counterparty $4,438, representing $3.17 per share for each of 1,400 Common Shares subject to the agreement, equal to the difference between $64,400, the price for the Common Shares on the accelerated settlement date determined with reference to the tender offer price for the Common Shares on such date and $59,962, the price for the Common Shares when the agreement was entered into. Without admitting any legal obligation, Goldman Sachs or another wholly-owned subsidiary will remit appropriate profits, if any, to the Company.
- [F4]On August 17, 2007, upon the accelerated settlement of a security-based swap agreement in the form of a contract for difference entered into on April 11, 2007, GSI paid to its counterparty $63,489, representing $3.143 per share for each of 20,200 Common Shares subject to the agreement, equal to the difference between $929,200, the price for the Common Shares on the accelerated settlement date determined with reference to the tender offer price for the Common Shares on such date and $865,711, the price for the Common Shares when the agreement was entered into. Without admitting any legal obligation, Goldman Sachs or another wholly-owned subsidiary will remit appropriate profits, if any, to the Company.
- [F5]Immediately exercisable.
Documents
Issuer
BIOMET INC
CIK 0000351346
Entity typeoperating
IncorporatedIN
Related Parties
1- filerCIK 0000351346
Filing Metadata
- Form type
- 4
- Filed
- Sep 18, 8:00 PM ET
- Accepted
- Sep 19, 6:43 PM ET
- Size
- 13.2 KB